
Opinion|Videos|January 13, 2025
Emerging Therapies: a look at the current data: APPLAUSE
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.
Advertisement
Episodes in this series

- In the phase 3 ALIGN trial (
NCT04573478 ), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH
3
Diabetes Dialogue: Signos and the Science of Weight Loss
4
Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework
5























































































